Evidence map›Paper›PMID 37074441›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Norovirus Disease Among Children <5 Years in 3 Sub-Saharan African Countries: Findings From the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018.

Richard Omore, Helen Powell, Samba O Sow, M Jahangir Hossain, Billy Ogwel, Sanogo Doh, John B Ochieng, Joquina Chiquita M Jones, Syed M A Zaman, Alex O Awuor and 22 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The Enterics for Global Health (EFGH)Open forum infectious diseases · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 7 institutions in 4 countries.

Richard OmoreKenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.
Helen PowellDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Samba O SowCentre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.
M Jahangir HossainMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Billy OgwelKenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.
Sanogo DohCentre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.
John B OchiengKenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.
Joquina Chiquita M JonesMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Syed M A ZamanMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Alex O AwuorKenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.
Jane JumaKenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.
Irene N KasumbaDepartment of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Anna RooseDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Leslie P JamkaDepartment of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Dilruba NasrinDepartment of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jie LiuDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Adama Mamby KeitaCentre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.
Awa TraoréCentre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.
Uma OnwuchekwaCentre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.
Henry BadjiMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Golam SarwarMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Martin AntonioMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Ciara E SugermanDivision of Foodborne, Waterborne, and Environmental Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Eric D MintzDivision of Foodborne, Waterborne, and Environmental Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Eric R HouptDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Jennifer R VeraniDivision of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.
Marc-Alain WiddowsonDivision of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.
Sharon M TennantDepartment of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
James A Platts-MillsDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Jacqueline E TateDivision of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Umesh D ParasharDivision of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Karen L KotloffDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Centre Pour le Développement des Vaccins-Mali · MLMRC Unit the Gambia · GMUniversity of Maryland, Baltimore · USKenya Medical Research Institute · KECenters for Disease Control and Prevention · USUniversity of Virginia · USCenters for Disease Control and Prevention · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo address a paucity of data from sub-Saharan Africa, we examined the prevalence, severity, and seasonality of norovirus genogroup II (NVII) among children <5 years old in The Gambia, Kenya, and Mali following rotavirus vaccine introduction.

methodsPopulation-based surveillance was conducted to capture medically-attended moderate-to-severe diarrhea (MSD) cases, defined as a child 0-59 months old passing ≥3 loose stools in a 24-hour period with ≥1 of the following: sunken eyes, poor skin turgor, dysentery, intravenous rehydration, or hospitalization within 7 days of diarrhea onset. Diarrhea-free matched controls randomly selected from a censused population were enrolled at home. Stools from cases and controls were tested for enteropathogens, including norovirus and rotavirus, by TaqMan quantitative polymerase chain reaction (PCR) and conventional reverse transcription PCR. We used multiple logistic regression to derive adjusted attributable fractions (AFe) for each pathogen causing MSD, which takes into consideration the prevalence in both cases and controls, for each site and age. A pathogen was considered etiologic if AFe was ≥0.5. In further analyses focusing on the predominant NVII strains, we compared rotavirus and NVII severity using a 20-point modified Vesikari score and examined seasonal fluctuations.

resultsFrom May 2015 to July 2018, we enrolled 4840 MSD cases and 6213 controls. NVI was attributed to only 1 MSD episode. NVII was attributed to 185 (3.8%) of all MSD episodes and was the sole attributable pathogen in 139 (2.9%); peaking (36.0%) at age 6-8 months with majority (61.2%) aged 6-11 months. MSD cases whose episodes were attributed to NVII alone compared with rotavirus alone were younger (median age, 8 vs 12 months, P < .0001) and had less severe illness (median Vesikari severity score, 9 vs 11, P = .0003) but equally likely to be dehydrated. NVII occurred year-round at all study sites.

conclusionsInfants aged 6-11 months bear the greatest burden of norovirus disease, with NVII predominating. An early infant vaccine schedule and rigorous adherence to guidelines recommended for management of dehydrating diarrhea may offer substantial benefit in these African settings.

Indexed as

NorovirusRotavirusRotavirus InfectionsRotavirus VaccinesCase-Control StudiesChildChild, PreschoolDiarrheaFecesHumansInfantInfant, NewbornKenyaRotavirus VaccinesAfricaburdenchildrendiarrheanorovirus

Identifiers

PMID37074441
PMCPMC10116553
OpenAlexW4366352782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.